Discovery of host-targeted covalent inhibitors of dengue virus

Antiviral Res. 2017 Mar;139:171-179. doi: 10.1016/j.antiviral.2016.12.017. Epub 2016 Dec 26.

Abstract

We report here on an approach targeting the host reactive cysteinome to identify inhibitors of host factors required for the infectious cycle of Flaviviruses and other viruses. We used two parallel cellular phenotypic screens to identify a series of covalent inhibitors, exemplified by QL-XII-47, that are active against dengue virus. We show that the compounds effectively block viral protein expression and that this inhibition is associated with repression of downstream processes of the infectious cycle, and thus significantly contributes to the potent antiviral activity of these compounds. We demonstrate that QL-XII-47's antiviral activity requires selective, covalent modification of a host target by showing that the compound's antiviral activity is recapitulated when cells are preincubated with QL-XII-47 and then washed prior to viral infection and by showing that QL-XII-47R, a non-reactive analog, lacks antiviral activity at concentrations more than 20-fold higher than QL-XII-47's IC90. QL-XII-47's inhibition of Zika virus, West Nile virus, hepatitis C virus, and poliovirus further suggests that it acts via a target mediating inhibition of these other medically relevant viruses. These results demonstrate the utility of screens targeting the host reactive cysteinome for rapid identification of compounds with potent antiviral activity.

MeSH terms

  • Antiviral Agents / chemistry*
  • Antiviral Agents / isolation & purification
  • Antiviral Agents / pharmacology*
  • Dengue / drug therapy
  • Dengue / virology
  • Dengue Virus / drug effects*
  • Drug Discovery*
  • Flavivirus / drug effects
  • Hepacivirus / drug effects
  • Host-Pathogen Interactions / drug effects*
  • Humans
  • Virus Replication / drug effects
  • West Nile virus / drug effects
  • Zika Virus / drug effects

Substances

  • Antiviral Agents